CK2B is a Prognostic Biomarker and a Potential Drug Target for Hepatocellular Carcinoma

作者：Huiru Dai, Huiru Dai, Minling Liu, Yuxi Pan, Tingwei Li, Yihang Pan, Zhe‐Sheng Chen, Jing Li, Jing Li, Yuchen Liu, Yuchen Liu, Shuo Fang, Shuo Fang · 发表于：Recent Patents on Anti-Cancer Drug Discovery · 年份：2023 · DOI：10.2174/0115748928262221230925090120 · 研究领域：Protein Kinase Regulation and GTPase Signaling、Wnt/β-catenin signaling in development and cancer、Cell Adhesion Molecules Research

Background: Although casein kinase II subunit beta (CK2B) was previously reported to be involved in human cancers, such as hepatocellular carcinoma (HCC), there has been no systematic assessment of CK2B in HCC. Objective: To assess the potential function of CK2B as a prognostic biomarker and possible druggable target in HCC. Methods: The Cancer Genome Atlas database was accessed to investigate the potential oncogenic and prognostic roles of CK2B in HCC. Diverse analytical methods were used to obtain a fuller understanding of CK2B, including CIBERSORT, The Tumor Immune Estimation Resource (TIMER), gene set enrichment analyses (GSEA), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene ontology (GO). Furthermore, the Comparative Toxicogenomic Database (CTD) was used to identify potential drugs to treat CK2B-overexpressing HCC. Patents for these drugs were reviewed using Patentscope® and Worldwide Espacenet®. Results: Upregulated CK2B expression was markedly associated with more aggressive pathological features, including G3, G4 (vs. G1, G2), and T2, T3 (vs. T1). Kaplan–Meier survival curves indicated that patients with HCC with higher expression of CK2B had worse overall survival (P = 0.005), progression-free interval (P = 0.001), and disease-specific survival (P = 0.011). GO and KEGG analysis revealed that CK2B dysregulation affects mitotic chromosome condensation, protein stabilization and binding, regulation of signal transduction of p53 class mediator, and cancer-relat...